457097-93-7

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-amino-3-(trifluoromethoxy)benzoate is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with improved properties.
Used in Agrochemical Industry:
Methyl 4-amino-3-(trifluoromethoxy)benzoate is used as an intermediate in the synthesis of agrochemicals, such as pesticides and herbicides, due to its potential to enhance the effectiveness of these products.
Used in Organic Synthesis:
Methyl 4-amino-3-(trifluoromethoxy)benzoate is used as a building block in the production of various organic compounds, allowing for the creation of a wide range of chemical products with different applications.

Upstream product

• 175278-22-5 4-amino-3-(trifluoromethoxy)benzoic acid 
• 186581-53-3 diazomethane 
• 67-56-1 methanol 
• 175278-09-8 4-bromo-2-(trifluoromethoxy)aniline 
• 201230-82-2 carbon monoxide 

Downstream Products

• 957206-36-9 4-bromo-3-trifluoromethoxy-benzoic acid methyl ester 
• 1261444-00-1 methyl 4-chloro-3-(trifluoromethoxy)benzoate 
• 886500-50-1 4-chloro-3-(trifluoromethoxy)benzoic acid 
• 1607024-35-0 ethyl 3-[4-chloro-3-(trifluoromethoxy)phenyl]-3-oxopropanoate 
• 1607022-88-7 5-[4-chloro-3-(trifluoromethoxy)phenyl]-3-(5-methyloxazol-2-yl)-4H,7H-pyrazolo[1,5-a]pyrimidin-7-one 
• 1378869-35-2 1-bromo-4-(bromomethyl)-2-(trifluoromethoxy)benzene 
• 1011531-67-1 (4-bromo-3-(trifluoromethoxy)phenyl)methanol 

Relevant academic research and scientific papers

Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY

Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).

SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME

The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

NOVEL INHIBITORS OF HEPATITIS C VIRUS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE

To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.